TIDMSBTX
RNS Number : 7973Z
SkinBioTherapeutics PLC
26 May 2021
26 May 2021
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Positive data for AxisBiotix-Ps(TM) food supplement consumer
study unveiled
-- Positive feedback from participants with a range of skin conditions;
-- Participants who self-identified as having psoriasis reported:
o Reductions in skin itchiness (76%), redness (75%),
irritability (73%), flakiness (65%);
o Noticeable improvements in overall feelings of health and
wellness.
-- No safety concerns;
-- Pre-registration open for customers at www.axisbiotix.com ;
-- Commercial preparations underway for launch in Q4 2021.
SkinBioTherapeutics plc (AIM: SBTX ) , a life science company
focused on skin health, announces that AxisBiotix Limited
("AxisBiotix"), a wholly owned subsidiary of the Company, has
finalised the analysis of the data from its AxisBiotix-Ps(TM) food
supplement consumer study. Participant feedback was highly positive
and there were no safety concerns.
AxisBiotix, with its partner Winclove Probiotics B.V., developed
a proprietary blend of bacterial strains in the form of a food
supplement called AxisBiotix-Ps(TM) . The powdered supplement is
specifically designed to modulate the immune system by harnessing
the gut-skin axis, to address problems associated with sensitive
skin conditions such as psoriasis.
Study results
The 56 day 'self-managed' consumer study of the food supplement
blend, AxisBiotix-Ps(TM), commenced in February 2021. The
participants that self-identified as suffering from psoriasis and
completed the study reported the following results:
-- 76% reported that their skin felt less itchy;
-- 75% reported that their skin appeared less red;
-- 73% reported that their skin felt less irritable; and
-- 65% reported that they had fewer 'flaky patches' of skin.
Participants who responded positively about their skin health,
also reported positive changes to their lifestyle. On average, at
day 56:
-- 62% reported having more energy;
-- 64% reported better sleep; and
-- 66% reported positive changes to their general mood.
Of participants that enrolled onto the study, 177 identified
themselves as suffering from mild to moderate psoriasis. Of these,
142 commenced the study and completed the day 7 questionnaire with
91 reporting for the entire 56 day study period. The study results
are calculated on the basis of the feedback from the 91
participants who reported for the entire period.
Prof. Cath O'Neill, Chief Scientific Officer of
SkinBioTherapeutics, said:
"The results have exceeded our expectations, with improvements
across all the key markers for irritable skin conditions like
psoriasis - from skin itchiness to redness and the level of flaky
patches. We have also received highly positive feedback from
participants about improvements to their sense of wellbeing, such
as being able to sleep better and pursuing activities they enjoyed
before, such as painting, long walks and even wearing shorts, which
they had given up because of their condition.
"I would like to thank the team and recognise their
determination and skill to execute the AxisBiotix-Ps(TM) consumer
study in very challenging circumstances presented by COVID-19. This
required a rapid switch from a clinical-based study to a home-based
one, using a mobile app."
Commercial plans - next steps
SkinBioTherapeutics, through its subsidiary, AxisBiotix, is
targeting a commercial launch of the
AxisBiotix-Ps(TM) product in Q4 2021.
The strategy for launch will be a monthly subscription model and
during the first phase rollout will be controlled to both establish
the supply chain and ensure subscribers have a reliable and
consistent supply of product.
AxisBiotix will be seeking regulatory approval for the product
as a food supplement in parallel in the UK, US and Europe, with the
intention to launch within these regions post the respective
approvals.
The Company will update on the plans for commercialisation,
including targeted levels of subscribers during the initial launch
period, within 90 days of this announcement.
AxisBiotix is encouraging individuals to pre-register for the
product prior to its launch at www.axisbiotix.com .
Stuart Ashman, CEO of SkinBioTherapeutics, said:
"I am delighted with the results of the study; the data and
testimonials are hugely encouraging. The next step for the Company
is to drive forward the commercialisation process in order to
launch the product in Q4 this year. Given this is a food supplement
and as such needs to taken on a daily basis, we want customers to
know that it will always be available to them, therefore,
initially, we will be releasing subscriptions on a controlled basis
to ensure a robust supply line. We therefore urge anyone interested
in AxisBiotix-Ps(TM) to pre-register at www.axisbiotix.com .
"I am extremely proud that over the past 18 months, despite a
global pandemic, we have evolved from being a wholly
research-focused company to readying for our first commercial
launch. This will be our first product on the market when it is
launched later this year. We also have a range of other development
programmes coming through. This a very exciting time for
SkinBioTherapeutics."
To watch the SkinBioTherapeutics team talk through the results
and listen to a selection of participants speak about their
experience with AxisBiotix-Ps(TM), together with a full summary of
the results, please visit the AxisBiotix website:
www.axisbiotix.com .
-Ends-
The information communicated within this announcement is deemed
to constitute inside information as stipulated under the Market
Abuse Regulations (EU) No. 596/2014 and has been arranged for
release by Doug Quinn, CFO of the Company. Upon the publication of
this announcement, this inside information is now considered to be
in the public domain.
For more information please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161
Stuart J . Ashman, CEO 468 2760
Doug Quinn, CFO
Dr Cath O'Neill, CSO
Cenkos Securities Plc (Nominated Adviser Tel: +44 (0) 20 7397
& Broker) 8900
Giles Balleny, Max Gould (Corporate Finance)
Michael Johnson (Sales)
Instinctif Partners (financial press) Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Phillip Marriage 2020
/ Nathan Billis Mob: +44 (0) 7890
022 814
SkinBio@instinctif.com
Vane Percy (Healthcare press)
Sarah Roberts / Amanda Bernard Tel: +44 (0) 1737
821890
Mob: + 44 (0) 77763
73269
sarah@vanepercy.com
/
amanda@vanepercy.com
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by Prof. Catherine
O'Neill and Professor Andrew McBain.
The Company has demonstrated, through scientific testing, that
the SkinBiotix(R) platform can improve the barrier effect of skin
models, protect from infection and repair wounds. Proof of
principle studies have also shown that the SkinBiotix(R) platform
has beneficial attributes applicable to each of these areas. The
technology achieved positive results in clinical studies in human
volunteers in early 2019.
The Company listed on AIM in April 2017 and is based in
Manchester, UK. For more information, visit: www.skinbiotix.com
.
About Psoriasis
Psoriasis is an autoimmune condition, which causes symptoms on
the skin and sometimes the joints. It is caused by an acceleration
of the skin replacement process, taking just a few days to replace
skin cells that usually take 21-28 days. As a result of this
process, there is an accumulation of skin cells that build up and
result in raised 'plaques' on the skin. These plaques can be itchy,
flaky, scaly and can look red on caucasian skin or darker patches
on darker skin tones. Psoriasis can occur on any area of the body,
including the scalp, hands, feet and back.
Incidence: psoriasis is believed to affect between 2-3% of the
UK population (c.1.8 million people) and up to 125 million people
worldwide [source: www.psoriasis.org]. The condition can occur at
any age and currently, there is no cure - mainstay treatments are
typically steroid or immuno suppressant-based.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBRGDUUDDDGBU
(END) Dow Jones Newswires
May 26, 2021 02:00 ET (06:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Skinbiotherapeutics (LSE:SBTX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024